Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...1920212223242526272829...143144»
  • ||||||||||  azenosertib (ZN-c3) / Zentalis Pharma
    New P1/2 trial, Combination therapy, Metastases:  ZN-c3 in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 24, 2023   
    P1/2,  N=82, Not yet recruiting, 
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion:  Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM (clinicaltrials.gov) -  Feb 15, 2023   
    P2,  N=176, Completed, 
    Unknown status --> Completed Recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  QUantitative Assessment of Swallowing After Radiation (QUASAR) (clinicaltrials.gov) -  Feb 10, 2023   
    P=N/A,  N=42, Recruiting, 
    Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Nov 2025 Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Dec 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Therapy with Cetuximab in Laryngeal Carcinoma: May HER1 Be Useful in the Bioselection of Patients? () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_336;    
    BioRT with cetuximab showed a reduction in the risk of lymph node relapse, particularly in the case of HER1 positive tumors, and it allowed to achieve a higher rate of functional larynx preservation and a higher salvageability compared with upfront surgery. Conclusion HER1 analysis could be clinically useful in the bioselection of tumors that may benefit from BioRT with cetuximab, particularly in those with neck node metastatic propensity.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Salvage chemotherapy after immunotherapy in recurrent/metastatic head and neck carcinoma () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_323;    
    In the MVA, only PDL1 status significantly impacted on independent prognostic factor for PFS (HR=0.25; IC95% 0.09-0.72; p=0.010) and OS (HR=0.31; IC95% 0.11-0.90; p 0.031) after adjusting by ECOG. Conclusion The ORR observed with SCT after immunotherapy was higher than expected regarding the pivotal trials, and is associated with better outcomes in terms of PFS and OS, especially in PDL1 positive pts.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Squamous Cell Carcinoma of Unknown Primary: Tonsillectomies, Radiotherapy, and Primary Emergence () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_302;    
    Most patients also received concurrent systemic therapy, primarily platinum based (n=46) or cetuximab (n=1)...Conclusions In this cohort of patients with squamous cell carcinoma of unknown primary of the head and neck, none of whom underwent lingual tonsillectomy, and the majority of whom did not undergo palatine tonsillectomy, there was no patient with primary site emergence on follow-up. These data suggest there is a potential opportunity to minimize surgical procedures and restrict radiotherapy mucosal targets and doses, particularly in patients who present with p16/HPV positive disease.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Outcomes of curative treatment in elderly patients with locally advanced oropharynx cancer () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_253;    
    Two patients were treated with carboplatin and one with cetuximab instead, simultaneously with radiotherapy...There are some limitations of this study that should be noted, first the low number of patients, the lack of analysis of medical comorbidities and treatment interruptions because of toxicities. To sum up, the literature is not consensual about outcomes in elderly patients and more evidence is needed to take further conclusions.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Response pattern under palliative chemotherapy in R/M HNSCC () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_249;    
    Inclusion criteria consisted of recurrent metastatic head and neck squamous cell carcinoma having received either platinum, 5-FU, cetuximab (PFC) or docetaxel, cisplatin, cetuximab (TPEx) 6 or 4 cycles respectively...It is unclear whether the continuation of chemotherapy over 2/3 cycles translates in a survival benefit. Especially in the light of the treatment associated toxicities and quality of life, short courses of therapy compared with SoC should be prospectively evaluated.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Head and neck cancer treatment: is cetuximab the best option for patients unfit for cisplatin? () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_208;    
    Especially in the light of the treatment associated toxicities and quality of life, short courses of therapy compared with SoC should be prospectively evaluated. Therefore, this work found important severe toxicity with the cetuximab treatment, which makes us think that it
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Real-world R/M HNSCC patients () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_205;    
    Cetuximab was used in 151 patients...Nearly all patients attended oncology consultations and only 66% were followed by a multidisciplinary team, essential for patient treatment and management due to the high complexity of the disease. This study provides the first real-world characterization of R/M HNSCC patients undergoing first line treatment in Portugal contributing to further understanding the therapeutic value of the different treatment modalities in clinical practice settings.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Real-world healthcare resources utilization costs associated with R/M HNSCC patients in Portugal () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_204;    
    This study provides the first real-world characterization of R/M HNSCC patients undergoing first line treatment in Portugal contributing to further understanding the therapeutic value of the different treatment modalities in clinical practice settings. Total HCRU costs included chemotherapy (91.4%), cetuximab (54.5%), immunotherapy (17.2%), radiotherapy (26.3%), lab tests (96.5%), imaging exams (92.0%), hospitalisations (68.1%), emergency (59.3%), outpatient consultations (94.4%) and other appointments (59.0%), were estimated as
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Oropharyngeal Cancer in the Elderly: Predictors of Survival in a Single-Center Cohort Study () -  Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_184;    
    Conclusion In both younger and elderly patients, overall survival was not better in patients treated with BRT compared to those treated with RT. These results question the role of cetuximab as a substitute for cisplatin as part of CRT
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, PD(L)-1 Biomarker, IO biomarker:  Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression. (Pubmed Central) -  Feb 7, 2023   
    Furthermore, exosomes derived from CRC/MDR cells decreased sensitivity to cetuximab via the activation of PI3K/AKT signaling, which promoted Sox2 and programmed death-ligand 1 (PD-L1) mRNA and protein expression according to reverse transcription-quantitative PCR, western blotting and immunohistochemistry analyses, as well as apoptosis resistance both in vitro and in vivo according to a TUNEL assay. In conclusion, the results of the present study demonstrated that exosomes derived from CRC/MDR cells may promote cetuximab resistance in KRAS wild-type cells via activation of the PI3K/AKT signaling pathway-mediated expression of Sox2 and PD-L1, which will be useful for investigating a potential clinical target in predicting cetuximab resistance.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    Journal:  Two Cases of Recurrent Colon Cancer with BRAF Mutation (Pubmed Central) -  Feb 4, 2023   
    Case 2, a 67-year-old man with diagnosis of peritoneal dissemination at 8 months after curative resection, received encorafenb and cetuximab (doublet-therapy) with certain effect, nevertheless advanced triplet-therapy with binimetinib was forced to pause due to severe skin disorders and he died on 123 days after recurrence. We considered that closed follow- up should be required after curatively resected colorectal cancers with BRAF mutation for early detection of recurrence, and prompt induction and evaluation of systemic treatment also should be required after unresectable recurrence including careful management with the attention to the features of doublet and triplet-therapy.